Tapan Kadia, MD, The University of Texas MD Anderson Cancer Center, Houston, TX, discusses the impact of RAS mutations in patients with acute myeloid leukemia (AML) and how these mutations play a role in mechanisms of resistance to various therapies. Dr Kadia then goes on to explain optimal treatment approaches for patients with RAS mutations, highlighting the advantage of cytarabine-based regimens. This interview took place at the Tenth Annual Meeting of the Society of Hematologic Oncology (SOHO) held in Houston, TX.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.